Log in

Event information

  • Home
  • Esophageal Cancer Virtual Tumour Board | ISDE Virtual Presentation

Esophageal Cancer Virtual Tumour Board | ISDE Virtual Presentation

  • 20 Aug 2020
  • 1:30 PM - 3:00 PM (UTC+01:00)
  • Virtual Presentation

A case-based discussion on the multi-modal treatment of locally advanced esophageal adenocarcinoma, squamous cell carcinoma, esophago-gastric junction tumours, and surgical complication management.

This virtual presentation will take place on Thursday, August 20 at 12:30 - 2:00 PM GMT.

  • Los Angeles 05:30-07:00  PDT
  • New York 08:30-10:00 EDT
  • London  13:30-15:00  BST
  • Hong Kong 20:30-22:00  HKT
  • Tokyo 21:30-23:00 JST

Register For Free


Moderated by


Mark van Berge Henegouwen, Amsterdam University Medical Center (Netherlands) 

Professor dr. Mark I. van Berge Henegouwen is chair of the Dutch Upper GI Cancer Audit and chair of the Dutch society of foregut surgeons of the Netherlands. He was appointed professor of Gastrointestinal Surgery in 2017 at the University of Amsterdam at the Amsterdam University Medical Centers.

Mark van Berge Henegouwen, born and raised in the Netherlands, received his MD and PhD at the University of Amsterdam. He performed his fellowship in gastrointestinal, upper GI and minimally invasive surgery at the Academic Medical Center in Amsterdam where he started as senior consultant in 2006.

Mark van Berge Henegouwen’ s clinical practice is dedicated to patients with malignancies of the esophagus and stomach. The Amsterdam UMC is currently one of the largest centers for esophageal and gastric cancer in Europe. The Amsterdam UMC is a tertiary referral center for these patients with around 250 esophago-gastric resections annually. Mark van Berge Henegouwen has introduced minimally invasive surgery for esophageal and gastric cancer at his center in 2009 and now around 90 percent of patients is treated thoraco-laparoscopically or robotically.

Mark van Berge Henegouwen is a Principal Investigator in upper GI cancer Surgery and main research activities are focused on improvement of outcomes in upper GI cancer surgery, outcomes and centralization in the Dutch Upper GI Cancer Audit, improvement of (minimally invasive) techniques, neoadjuvant treatment regimens in esophageal and gastric cancer and quality of life in upper GI cancer surgery.


Lorenzo Ferri, McGill University (Canada).

 Lorenzo Ferri is the David S. Mulder Chair in Surgery and a Professor in the Departments of Surgery and Oncology at McGill University in Montreal Canada. He is director of the Division of Thoracic Surgery and heads the Upper Gastrointestinal Cancer Program at McGill University, one of North America’s largest and most comprehensive. Dr Ferri couples this clinical activity with an active translational and fundamental research program investigating the inflammatory basis of cancer progression and is the recipient of numerous peer review grants, including the Canadian Institutes of Health Research, Canadian Cancer Society, and Cancer Research UK. Through this work he has identified the important role of bacterial antigens - pattern recognition proteins (TLRs and NODs) and host neutrophils/Neutrophil Extracellular Traps in propagating cancer dissemination, thus representing a new paradigm in the metastatic process. In addition, Dr Ferri is Work Package leader on a Cancer Research UK Grand Challenge, one of the world’s largest cancer grants (20 million Pounds Sterling), investigating the inflammatory basis of Barrett’s Esophageal Adenocarcinoma.  

Expert Panel

Wayne Hofstetter, MD Anderson Cancer Center (USA)

Wayne L. Hofstetter, M.D., is currently Professor and Deputy Chair in the Department of Thoracic and Cardiovascular Surgery and serves as Director of the Esophageal Surgery Program. Broadly trained as a cardiothoracic surgeon and thoracic oncologist at the Texas Heart Institute, he now devotes a great deal of his work to esophageal cancer and lung cancer.

Dr. Hofstetter is a leading proponent of surgical and multidisciplinary approaches to esophageal cancer and minimally invasive approaches to lung cancer, bringing to the institution his unique clinical skills in MIS approaches to thoracic surgery.

Board certified both by the American Board of Surgery and the American Board of Thoracic Surgery, Dr. Hofstetter is nationally and internationally involved in a host of clinical and scientific endeavors with membership in several organizations, the Society for Surgery of the Alimentary Tract, the General Thoracic Surgical Club, the American Association for Thoracic Surgery, including the Society of Thoracic Surgeons, and the International Association for the Study of Lung Cancer. His research, which forms a vital part of his academic role, has led to numerous peer-reviewed publications, notably in such journals as the Journal of Thoracic and Cardiovascular Surgery, Annals of Thoracic Surgery, and Cancer.

Simon Law, University of Hong Kong, (China)

Simon Law graduated from the University of Cambridge in England and is currently Cheung Kung-Hai Professor in Gastrointestinal Surgery, Chair and Chief of the Division of Esophageal and Upper Gastrointestinal Surgery at The University of Hong Kong.

Professor Law has been active with ISDE since the early 1990s. He has served as co-chairman of the scientific committee for the ISDE world congress in Vancouver in 2014. Currently he is Associate Editor for Diseases of the Esophagus, and co-chairman of the Education Committee. Actively involved in the development of many international initiatives on esophageal surgery, he was a member of the Worldwide Esophageal Cancer Collaboration, Esophageal Complication Consensus Group, and working group on Enhanced Recovery after Esophagectomy. Engaging with other societies, he also holds positions, such as Consultant for International Society of Digestive Surgery, National Delegate to the International Surgical Society, Secretary General of the American College of Surgeons (Hong Kong Chapter), Asia II Representative of the Member Services Committee of the Society for Surgeons of the Alimentary Tract (SSAT). 

He has concentrated his experience and research in both benign and malignant upper gastrointestinal tract disorders. He has published over 300 articles, and 36 book chapters. He is member of the editorial board in 15 journal.

John Reynolds, Trinity College Dublin (Ireland)

Professor Reynolds is Professor of Clinical Surgery at the St. James’s Hospital and Trinity College Dublin. He is the National Lead for esophageal and gastric cancer. He is Cancer Lead at St. James’s Hospital and the Trinity School of Medicine, and a Principal Investigator in the Trinity Translational Medicine Institute. He has formerly held Fellowship positions with the University of Pennsylvania and Wistar Institute in Philadelphia and at the Memorial Sloan-Kettering Cancer Centre in New York. He was a Senior Lecturer at St James’s University Hospital in Leeds (1994-6).

Professor Reynolds bas obtained numerous research awards and has published widely in cancer research, with over 250 publications and approximately €5m research grant income. His clinical interest is in diseases of the esophagus and stomach.

His research interest is in four areas:

  1. pathogenesis of Barrett’s esophagus and progression;
  2. prediction of response and resistance to chemotherapy and radiation therapy;
  3. obesity, altered metabolism, and cancer;
  4. malnutrition and peri-operative nutrition.

Mark Smithers, University of Queensland (Australia)

Mayne Professor and Head of the Discipline of Surgery, Faculty of Medicine, University of Queensland. Director of the Upper GI and Soft Tissue Surgical unit, Princess Alexandra Hospital and the Past President, Australia and New Zealand Gastric and Oesophageal Surgeons Association (ANZGOSA). Co-chair, Publication & Audit Subcommittee of the Research & Database Committee, International Society for Diseases of the Esophagus (ISDE).

Involved with the development of minimally invasive surgery for upper gastro-intestinal tract pathology, including benign hiatal surgery and esophageal resection. Clinical and research focus on the multidisciplinary evidence-based management of cancer of the oesophagus and stomach. Chief investigator on a number of grants assessing the epidemiology and management of oesophageal and gastric cancer (NIH, USA and NH&MRC, Australia) and lead surgical investigator in a number of Phase II and III trials relating to the role of neoadjuvant therapy for esophago-gastric cancer. Most recently surgical principle investigator of an international a multi-centre randomised trial assessing the role of preoperative chemo-radiation for locally advanced gastric cancer.

In 2018, became a Member of the Order of Australia for service to medicine in the fields of gastro-intestinal and melanoma surgery, to medical education and to professional organisations.

Yuko Kitagawa, Keio University (Japan)

Professor and Chairman of Department of Surgery, Keio University, School of Medicine General Director of Keio University Hospital, Tokyo, Japan

Dr. Kitagawa is a surgical oncologist and clinical and translational researcher, mainly in the areas of gastrointestinal cancers. He is a chair of Japan Esophageal Oncology Group and working as a principal investigator for several important nation-wide clinical studies for multimodal treatment for esophageal cancer. He used be an Editor in Chief of the official journal of Japan Gastric Cancer Association and International Gastric Cancer Association, "Gastric Cancer" and an Associate Editor of the official journal of ISDE, "Diseases of the Esophagus".

Currently professor Kitagawa is working as a member of Executive Council of various important societies such as International Society for Diseases of the Esophagus (ISDE), the Japanese Society of Gastroenterological Surgery, Japan Esophageal Society and Japan Society for Endoscopic Surgery. He has organized 120th Annual Meeting of Japan Surgical Society in 2020 and 16th ISDE meeting in 2018 in Vienna.


Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software